6.82
+0.065(+0.96%)
Currency In USD
| Previous Close | 6.75 |
| Open | 6.77 |
| Day High | 6.94 |
| Day Low | 6.76 |
| 52-Week High | 7.32 |
| 52-Week Low | 3.93 |
| Volume | 145,573 |
| Average Volume | 1.23M |
| Market Cap | 348.63M |
| PE | -10.82 |
| EPS | -0.63 |
| Moving Average 50 Days | 6.19 |
| Moving Average 200 Days | 5.79 |
| Change | 0.07 |
If you invested $1000 in Abeona Therapeutics Inc. (ABEO) 10 years ago, it would be worth $45.43 as of July 30, 2025 at a share price of $6.815. Whereas If you bought $1000 worth of Abeona Therapeutics Inc. (ABEO) shares 5 years ago, it would be worth $94.33 as of July 30, 2025 at a share price of $6.815.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
GlobeNewswire Inc.
Jul 15, 2025 11:30 AM GMT
- Lucile Packard Children’s Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
GlobeNewswire Inc.
Jul 02, 2025 11:30 AM GMT
Cash resources totaled approximately $225 million as of June 30, 2025CLEVELAND, July 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
GlobeNewswire Inc.
Jul 01, 2025 11:30 AM GMT
Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royaltiesCLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophtha